Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dahuang Zhechong Pill (DHZCP) is a classic Traditional Chinese Medicine (TCM) formula originally described in the *Synopsis of Prescriptions of the Golden Chamber* (*Jin Gui Yao Lue*). It is composed of 12 medicinal ingredients, including Rhubarb (*Radix et Rhizoma Rhei*) and Ground Beetle (*Eupolyphaga seu Steleophaga*). Traditionally used to treat "blood stasis" and "dry blood" syndromes, modern research has focused on its antineoplastic properties. In the context of pancreatic cancer, DHZCP has been shown to inhibit the NF-κB/VEGF signaling pathway, thereby suppressing tumor cell proliferation, migration, and invasion. It also modulates the inflammatory microenvironment by reducing levels of pro-inflammatory cytokines like IL-17 and markers like amylase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dahuang zhechong pill.